Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625298 | 0.86 | — | — | |
| SCHEMBL7996738 | 0.84 | — | — | |
| SCHEMBL14289025 | 0.84 | — | — | |
| SCHEMBL5580158 | 0.84 | — | — | |
| SCHEMBL245633 | 0.80 | ALDH1A1 (0.48) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL6589055 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL11785454 | 0.78 | TSHR (0.39) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL5969554 | 0.78 | TSHR (0.46) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL8916103 | 0.78 | TSHR (0.46) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL7047690 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1698618-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-05-18 | — | — | EP | claimed |
| EP-0647137-B1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | UNIV CALIFORNIA (US) | 2008-08-13 | — | — | EP | claimed |
| US-6656910-B2 | Serine protease inhibitors | CORTECH, INC. | 2003-12-02 | — | — | US | claimed |
| US-20030060418-A1 | Serine protease inhibitors | CORTECH, INC. | 2003-03-27 | — | — | US | claimed |
| EP-1105412-A1 | SERINE PROTEASE INHIBITORS COMPRISING ALPHA-KETO HETEROCYCLES | CORTECH, INC. (US) | 2001-06-13 | — | — | EP | claimed |
| US-6159938-A | Serine protease inhibitors comprising α-keto heterocycles | CORTECH, INC. | 2000-12-12 | — | — | US | claimed |
| EP-0793674-B1 | HUMAN NEUTROPHIL ELASTASE INHIBITORS | CORTECH INC (US) | 2000-05-24 | — | — | EP | claimed |
| WO-2000009542-A1 | SERINE PROTEASE INHIBITORS COMPRISING α-KETO HETEROCYCLES | CORTECH, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| EP-0979242-A2 | SUBSTITUTED OXADIAZOLE CYSTEINE PROTEASE INHIBITORS | CORTECH, INC. (US) | 2000-02-16 | — | — | EP | claimed |
| US-6015791-A | Serine protease inhibitors-cycloheptane derivatives | CORTECH INC. (US) | 2000-01-18 | — | — | US | claimed |
| US-5869455-A | SUBSTITUTED OXADIAZOLE, THIADIAZOLE AND TRIAZOLE PEPTOIDS WHICH ARE USEFUL AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE | CORTECH, INC. (US) | 1999-02-09 | — | — | US | claimed |
| US-5861380-A | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE PEPTOIDS AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIARTHRITIC,-INFLAMMATORY,-ISCHEMIC,-TUMOR AND -CARCINOGENIC AGENTS AND OTHER HNE-MEDIATED CONDITIONS | CORTECH, INC. (US) | 1999-01-19 | — | — | US | claimed |
| US-5843905-A | Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-01 | — | — | US | claimed |
| WO-1998049190-A2 | SUBSTITUTED OXADIAZOLE CYSTEINE PROTEASE INHIBITORS | CORTECH, INC. (US) | 1998-11-05 | — | — | WO | claimed |
| US-5807829-A | RESPIRATORY SYSTEM DISORDERS; SESPIC SHOCK; ORGAN FAILURE | CORTECH, INC. (US) | 1998-09-15 | — | — | US | claimed |
| EP-0644197-B1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | VERTEX PHARMA (US) | 1998-09-09 | — | — | EP | claimed |
| US-5801148-A | Serine protease inhibitors-proline analogs | CORTECH, INC. (US) | 1998-09-01 | — | — | US | claimed |
| WO-1998024806-A2 | SUBSTITUTED OXADIAZOLE, THIADIAZOLE AND TRIAZOLE SERINE PROTEASE INHIBITORS | CORTECH, INC. (US) | 1998-06-11 | — | — | WO | claimed |
| US-5677283-A | α-heteroaryloxymethyl ketones as interleukin - 1 β converting enzyme inhibitors | SANOFI (FR) | 1997-10-14 | — | — | US | claimed |
| EP-0644197-A1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-03-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060418-A1 | Serine protease inhibitors | PRSS1, SERPINB1, SERPINE1 | ALDH1A1 3127/4885TSHR 3616/4885SMN1; SMN2 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.